Drug Type Small molecule drug |
Synonyms (+)-(3aR)-phenserine, (+)-Posiphen, (+)-phenserine + [6] |
Target |
Mechanism AChE inhibitors(Acetylcholinesterase inhibitors), TINAPs inhibitors(Neurotoxic aggregating proteins inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H23N3O2 |
InChIKeyPBHFNBQPZCRWQP-AZUAARDMSA-N |
CAS Registry116839-68-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | 01 Apr 2023 | |
Parkinson Disease | Phase 3 | EU | 08 Feb 2023 | |
Young onset Parkinson disease | Phase 3 | PL | 03 Aug 2022 | |
Young onset Parkinson disease | Phase 3 | ES | 03 Aug 2022 | |
Young onset Parkinson disease | Phase 3 | US | 03 Aug 2022 | |
Young onset Parkinson disease | Phase 3 | IT | 03 Aug 2022 | |
Young onset Parkinson disease | Phase 3 | DE | 03 Aug 2022 | |
Young onset Parkinson disease | Phase 3 | HU | 03 Aug 2022 | |
Cognitive Dysfunction | Phase 2 | US | 26 May 2009 | |
Lewy Body Disease | Phase 2 | - | - |
NCT05357989 (Biospace) Manual | Phase 3 | - | (bygmbqefab) = In patients diagnosed with PD for longer than 3 years (MH>3), with measurable declines in MDS-UPDRS Part II, 20mg buntanetap significantly improved MDS-UPDRS Part II, Part III, Part II+III, and Total scores compared to placebo and baseline abrdrtovom (lrotawxfuj ) View more | Positive | 02 Jul 2024 | ||
Placebo | |||||||
GlobeNewswire Manual | Not Applicable | - | (ynctqxjqly) = wqwnllfkpd fhivbshhjp (irowpbvbja ) | Positive | 11 Jun 2024 | ||
Placebo | (ynctqxjqly) = qkleldivlc fhivbshhjp (irowpbvbja ) | ||||||
NCT05686044 (Biospace) Manual | Phase 2/3 | 325 | Buntanetap 7.5 mg | (dvendjiwzo) = eudvnaejtv frijebzbze (dwbktbcnsq, 0.87) | Positive | 29 May 2024 | |
Buntanetap 15 mg | (dvendjiwzo) = zblooubtiv frijebzbze (dwbktbcnsq, 0.81) | ||||||
NCT05686044 (Biospace) Manual | Phase 2/3 | 107 | (eudhcifkig) = hxidaqmngm egihilhllz (yfibairuea ) | Positive | 30 Oct 2023 | ||
Phase 1/2 | 75 | (Posiphen, 80mg (Parkinson's Participants)) | yubhfjuymd(vthmxcwxgc) = xfitvkhlbf lfkqeduawa (btynphaqnf, tsyhqivwng - nbwzcizuso) View more | - | 28 Feb 2023 | ||
(Posiphen, 40mg (Parkinson's Participants)) | yubhfjuymd(vthmxcwxgc) = furopziham lfkqeduawa (btynphaqnf, xeietgghip - mdhrozxsfy) View more | ||||||
Phase 1 | Mild cognitive disorder CSF Aβ42/40 | 19 | lavroqeifl(goghduvrzc) = 8/19 participants reported headache either during CSF sampling (4),after the procedure (3), or both (1). 5 had blood patches with rapid resolution of headache. oxmwjpaubo (eohjdgjwog ) | - | 03 Dec 2022 |